DK450484A - 2,5-disubstituerede-4(3h) pyrimidoner samt fremgangsmaader til fremstilling deraf - Google Patents

2,5-disubstituerede-4(3h) pyrimidoner samt fremgangsmaader til fremstilling deraf Download PDF

Info

Publication number
DK450484A
DK450484A DK450484A DK450484A DK450484A DK 450484 A DK450484 A DK 450484A DK 450484 A DK450484 A DK 450484A DK 450484 A DK450484 A DK 450484A DK 450484 A DK450484 A DK 450484A
Authority
DK
Denmark
Prior art keywords
pyrimidones
disubstituted
procedures
preparing
Prior art date
Application number
DK450484A
Other languages
English (en)
Other versions
DK162987C (da
DK450484D0 (da
DK162987B (da
Inventor
Aldo A Algieri
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of DK450484D0 publication Critical patent/DK450484D0/da
Publication of DK450484A publication Critical patent/DK450484A/da
Publication of DK162987B publication Critical patent/DK162987B/da
Application granted granted Critical
Publication of DK162987C publication Critical patent/DK162987C/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK450484A 1983-09-21 1984-09-20 5-amino-2-oe3-(3-piperidinomethylphenoxy)propylaminoaa-4(3h)-pyrimidon og farmaceutisk acceptable syreadditionssalte deraf DK162987C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/534,426 US4772704A (en) 1983-09-21 1983-09-21 2,5-disubstituted-4(3H)-pyrimidones having histamine H2 -receptor antagonist activity
US53442683 1983-09-21

Publications (4)

Publication Number Publication Date
DK450484D0 DK450484D0 (da) 1984-09-20
DK450484A true DK450484A (da) 1985-03-22
DK162987B DK162987B (da) 1992-01-06
DK162987C DK162987C (da) 1992-06-01

Family

ID=24129972

Family Applications (1)

Application Number Title Priority Date Filing Date
DK450484A DK162987C (da) 1983-09-21 1984-09-20 5-amino-2-oe3-(3-piperidinomethylphenoxy)propylaminoaa-4(3h)-pyrimidon og farmaceutisk acceptable syreadditionssalte deraf

Country Status (36)

Country Link
US (1) US4772704A (da)
JP (1) JPH0643310B2 (da)
KR (1) KR900001198B1 (da)
AR (2) AR242385A1 (da)
AT (1) AT387965B (da)
AU (1) AU583479B2 (da)
BE (1) BE900652A (da)
CA (1) CA1260463A (da)
CH (1) CH665840A5 (da)
CS (1) CS249147B2 (da)
CY (1) CY1561A (da)
DD (1) DD226881A5 (da)
DE (1) DE3434578A1 (da)
DK (1) DK162987C (da)
ES (4) ES8607253A1 (da)
FI (1) FI83868C (da)
FR (1) FR2552082B1 (da)
GB (1) GB2146994B (da)
GR (1) GR80439B (da)
HK (1) HK73790A (da)
HU (1) HU193227B (da)
IE (1) IE58083B1 (da)
IL (1) IL72990A (da)
IT (1) IT1176739B (da)
LU (1) LU85550A1 (da)
NL (1) NL8402898A (da)
NO (1) NO161561C (da)
NZ (1) NZ209572A (da)
OA (1) OA07820A (da)
PT (1) PT79256B (da)
SE (1) SE463209B (da)
SG (1) SG60890G (da)
YU (1) YU45205B (da)
ZA (1) ZA847345B (da)
ZM (1) ZM4984A1 (da)
ZW (1) ZW16084A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2873340B2 (ja) * 1988-04-29 1999-03-24 武田薬品工業株式会社 抗生物質tan―1057,その製造法および用途
WO2022034121A1 (en) 2020-08-11 2022-02-17 Université De Strasbourg H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN151188B (da) * 1978-02-13 1983-03-05 Smith Kline French Lab
ES477520A1 (es) * 1978-02-25 1979-06-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevas penicilinas.
PH16240A (en) * 1978-04-11 1983-08-11 Smith Kline French Lab Process for making histamine antagonist
US4496567A (en) * 1978-11-13 1985-01-29 Smith Kline & French Laboratories Limited Phenyl alkylaminopyrimidones
US4521418A (en) * 1979-02-21 1985-06-04 Smith Kline & French Laboratories Limited Guanidinothiazolyl derivatives
AU531142B2 (en) * 1979-04-04 1983-08-11 Smith Kline & French Laboratories Limited 2 amino- pyimindones
CA1140129A (en) * 1979-08-21 1983-01-25 Ronald J. King 4-pyrimidone derivatives
ZW21281A1 (en) * 1980-10-01 1981-11-18 Smith Kline French Lab Amine derivatives
US4352933A (en) * 1981-02-06 1982-10-05 Smithkline Beckman Corporation Chemical methods and intermediates for preparing substituted pyrimidinones
NZ202797A (en) * 1981-12-28 1985-08-30 Lilly Co Eli Pyrimidine derivatives and pharmaceutical compositions
US4468399A (en) * 1981-12-28 1984-08-28 Eli Lilly And Company 2-[2-(2-Aminoalkyl-4-thiazolylmethylthio)alkyl]-amino-5-substituted-4-pyrimidones
GB8320505D0 (en) * 1983-07-29 1983-09-01 Smith Kline French Lab Chemical compounds
CA1275097A (en) * 1984-10-02 1990-10-09 Fujio Nohara Pyridyloxy derivatives

Also Published As

Publication number Publication date
GB8423863D0 (en) 1984-10-24
FR2552082A1 (fr) 1985-03-22
AR242789A1 (es) 1993-05-31
IE58083B1 (en) 1993-06-30
BE900652A (fr) 1985-03-21
ES551500A0 (es) 1987-03-16
AU583479B2 (en) 1989-05-04
ES544213A0 (es) 1987-04-01
FR2552082B1 (fr) 1987-02-20
IT8422744A0 (it) 1984-09-20
ATA300984A (de) 1988-09-15
KR850002259A (ko) 1985-05-10
JPS6087271A (ja) 1985-05-16
SE463209B (sv) 1990-10-22
AU3335184A (en) 1985-03-28
GR80439B (en) 1985-01-22
ES536054A0 (es) 1986-05-16
HUT35259A (en) 1985-06-28
AT387965B (de) 1989-04-10
IT1176739B (it) 1987-08-18
CY1561A (en) 1991-03-22
YU45205B (en) 1992-05-28
FI843643A0 (fi) 1984-09-18
NO161561B (no) 1989-05-22
NL8402898A (nl) 1985-04-16
YU161384A (en) 1987-12-31
HU193227B (en) 1987-08-28
IE842406L (en) 1985-03-21
NO161561C (no) 1989-08-30
GB2146994B (en) 1987-09-03
HK73790A (en) 1990-09-28
DE3434578A1 (de) 1985-04-11
DK162987C (da) 1992-06-01
KR900001198B1 (ko) 1990-02-28
ZW16084A1 (en) 1985-01-16
SG60890G (en) 1990-09-07
DD226881A5 (de) 1985-09-04
AR242385A1 (es) 1993-03-31
FI843643L (fi) 1985-03-22
FI83868B (fi) 1991-05-31
ZA847345B (en) 1985-06-26
ES8704155A1 (es) 1987-03-16
FI83868C (fi) 1991-09-10
CS249147B2 (en) 1987-03-12
DK450484D0 (da) 1984-09-20
ZM4984A1 (en) 1985-05-21
CA1260463A (en) 1989-09-26
ES8702897A1 (es) 1987-01-16
US4772704A (en) 1988-09-20
PT79256A (en) 1984-10-01
LU85550A1 (fr) 1985-06-04
IT8422744A1 (it) 1986-03-20
ES551501A0 (es) 1987-01-16
JPH0643310B2 (ja) 1994-06-08
DK162987B (da) 1992-01-06
ES8607253A1 (es) 1986-05-16
NZ209572A (en) 1988-05-30
GB2146994A (en) 1985-05-01
SE8404729L (sv) 1985-03-22
OA07820A (fr) 1986-11-20
CH665840A5 (de) 1988-06-15
IL72990A (en) 1990-07-12
SE8404729D0 (sv) 1984-09-20
PT79256B (en) 1986-11-20
NO843726L (no) 1985-03-22
ES8704465A1 (es) 1987-04-01

Similar Documents

Publication Publication Date Title
NO171364C (no) N-aryl-3-aryl-4,5-dihydro-1h-pyrazol-1-karboksamider og fremgangsmaate til fremstilling derav, samt insektmiddel sominneholder karboksamidet
DK355485D0 (da) Dinatrium-3-amino-l-hydroxy-propan-1,1-diphosphonat samt fremgangsmaade til fremstilling deraf
DK165248C (da) 1,3,9,9a-tetrahydro-imidazooe4,5-baaquinolin-2-oner samt fremgangsmaade til fremstilling deraf
DK273587D0 (da) 1,5-diaryl-3-substituerede pyrazoler samt fremgangsmaade til fremstilling deraf
DK186981A (da) 17-substitueret-6-desoxy-7,8-dihydro-6alfa-methylnoroxymorphon samt fremgangsmaade til fremstilling deraf
DE3584271D1 (de) Elektrooptische vorrichtung.
DK445882A (da) Tryksager samt fremgangsmaade til fremstilling deraf
IL67537A0 (en) Modified vaccinia virus and methods for making and employing the same
DK476682A (da) Peptidforbindelser samt fremgangsmaade til fremstilling af samme
DK512184A (da) 5(3)-amino-6(substitueret phenyl)2,3(2,5)-dihydro-3(5)-imino-2-alkyl-1,2,4-triaziner samt fremgangsmaade til fremstilling deraf
NO853120L (no) Isfjell og fremgangsmaate for fremstilling av samme.
FI842139A0 (fi) Avskjutningsanordning foer gevaer.
DE3788494D1 (de) Harnstoffe.
FI852527A0 (fi) Alifatiska tioetrar.
DK431185D0 (da) Substituerede quinazolindioner samt fremgangsmaade til fremstilling deraf
NO853400L (no) Polypeptidvaksiner.
DK178182A (da) Heteropolysaccharid s-198, fremgangsmaade til fremstilling deraf samt dets anvendelse
DK450484D0 (da) 2,5-disubstituerede-4(3h) pyrimidoner samt fremgangsmaader til fremstilling deraf
DK102882A (da) Endo-deoxyribonuklease a samt fremgangsmaade til frembringelseaf samme
DE3675155D1 (de) Sulfoalkylierungsverfahren.
DK59583D0 (da) Mikroporoes hulfibermembran til plasmaferese samt fremgangsmade til fremstilling deraf
DK51785A (da) 1,4-aminoalkylamino-9h-thioxanthen-9-oner, laegemidler indeholdende disse samt fremgangsmaade til fremstilling deraf
DK56985D0 (da) Substituerede benzopentathiepiner, fremgangsmaade til fremstilling deraf samt mellemprodukter til anvendelse herved
DE3786790T2 (de) Qualitätskontrollsysteme.
DK191684D0 (da) Hydroxylerede diphenylazomethinderivater samt fremgangsmaade til fremstilling deraf